FGFR4
ENSG00000160867
Target class
Kinase
Chromosome
5
Approved drugs
5
Clinical candidates (approved and in development)
17
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- Yes
- Target name
- FGFR4
- Gene name
- Fibroblast growth factor receptor 4
- Gene symbol
- FGFR4
- Protein name
- Fibroblast growth factor receptor 4 (FGFR-4) (EC 2.7.10.1) (CD antigen CD334)
- JTK2
- CD334
- TKF
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|I-set domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 36
- Highest tissue expression
- 106.98
- Tissue specificity (Gini)
- 0.712
- Tissue specificity (tau)
- 0.932
- KEGG gene identifiers
- hsa:2264
- Protein interaction confidence
- 0.840947
- Protein interaction partners
- 75
- R-HSA-109704
- R-HSA-1257604
- R-HSA-1307965
- R-HSA-1839128
- R-HSA-190322
- R-HSA-2219530
- R-HSA-5654228
- R-HSA-5654712
- R-HSA-5654719
- R-HSA-5654720
- R-HSA-5654733
- R-HSA-5655291
- R-HSA-5673001
- R-HSA-6811558
- End position
- 177098151
- Start position
- 177086456
- Chromosome
- 5
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane.
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
- Tissue specificity (tau)
- 0.931883
- Expression inequality (Gini)
- 0.712446
Expression in transcripts per million
- Lung
- 106.98
- Liver
- 48.89
- Ovary
- 44.39
- Spleen
- 32.63
- Kidney - Cortex
- 32.59
Expression in transcripts per million
- Lung106.98
- Liver48.89
- Ovary44.39
- Spleen32.63
- Kidney - Cortex32.59
- Small Intestine - Terminal Ileum27.72
- Kidney - Medulla25.93
- Colon - Transverse21.86
- Pancreas16.8
- Adrenal Gland13.75
- Testis12.08
- Stomach8.49
- Brain - Cerebellum8.45
- Brain - Cerebellar Hemisphere7.79
- Cervix - Endocervix5.62
- Prostate5.47
- Fallopian Tube5.17
- Nerve - Tibial4.99
- Uterus4.78
- Cervix - Ectocervix4.57
- Vagina4.56
- Bladder4.27
- Colon - Sigmoid4.04
- Esophagus - Mucosa3.59
- Esophagus - Gastroesophageal Junction3.35
And 29 more, listed on the interactive page.
- GO:0008284
- GO:0008543
- GO:0010628
- GO:0010715
- GO:0016477
- GO:0018108
- GO:0043085
- GO:0045862
- GO:0046777
- GO:0070374
- GO:0070857
- GO:1903412
- GO:2000573
- GO:0005783
- GO:0005794
- GO:0005886
- GO:0005911
- GO:0030133
- GO:0004713
- GO:0005007
- GO:0005515
- GO:0008201
- GO:0017134
Related records
Trials (363)
- A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
- A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
- A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
- A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
- A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
- A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
- A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
- A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
- A Phase I Study of Oral BGJ398 in Asian Patients
- A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
- A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
- A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
- A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
- A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Drugs (18)
- Aldafermin FGFR4-KLB activator
- Brivanib Fibroblast growth factor receptor inhibitor
- Brivanib alaninate Fibroblast growth factor receptor inhibitor
- CP-459632 Fibroblast growth factor receptor inhibitor
- Derazantinib Fibroblast growth factor receptor inhibitor
- ENMD-981693 Fibroblast growth factor receptor inhibitor
- Erdafitinib Fibroblast growth factor receptor inhibitor
- Fexagratinib Fibroblast growth factor receptor inhibitor
- FGF401 Fibroblast growth factor receptor 4 inhibitor
- Futibatinib Fibroblast growth factor receptor inhibitor
- Infigratinib Fibroblast growth factor receptor inhibitor
- Infigratinib phosphate Fibroblast growth factor receptor inhibitor
- LY-2874455 Fibroblast growth factor receptor inhibitor
- Nintedanib Fibroblast growth factor receptor inhibitor
- Nintedanib esylate Fibroblast growth factor receptor inhibitor
- Orantinib Fibroblast growth factor receptor inhibitor
- Rogaratinib Fibroblast growth factor receptor inhibitor
- XL-999 Fibroblast growth factor receptor inhibitor